Abstract:Objective:To investigate the effects of long-acting somatostatin analogues (SSA) on glucose metabolism in acromegalic patients without diabetes and the influence factors.Methods:Clinical information of patients with growth hormone (GH) secreting adenomas were collected at pretreatment and 3 months after initiation of treatment with long-acting SSA in Huashan Hospital from January 2015 to June 2020. The patients were divided into normal glucose tolerance (NGT) group and prediabetes (preDM) group according to glucose metabolism. Insulin resistance and β cell function were compared among different glucose tolerance groups; changes in the characteristics of glucose metabolism after SSA treatment were analyzed. Subgroup analysis was performed according to changes of glucose metabolism after SSA treatment and analysis the factors affecting the changes of glucose metabolism. The patients were divided into three subgroups: blood glucose deteriorated group, blood glucose stable group and blood glucose improved group. Pearson analysis was used to evaluate the related factors affecting glucose metabolism. Paired t test or Wilcoxon rank sum test was conducted to compare the indexes before and after SSA treatment. Results:A total of 71 patients were enrolled in this study. There were 36 patients in NGT group, and 35 in preDM group. The fasting blood glucose increased after SSA treatment [(5.8±0.7) vs. (5.2±0.5) mmol/L P<0.05]. Homeostasis model assessment of insulin resistance declined [4.2(2.1, 6.3) vs. 2.3(1.3, 4.8), P<0.05] after SSA treatment. The glucose tolerance status deteriorated in 24 (33.8%) patients, including 16 patients in the NGT group and 8 patients in the preDM group. Deteriorated glucose tolerance status groups were younger than the stable glucose tolerance status groups [(37.4±11.8) and (45.7±12.5) years old, respectively]. The decrease of GH of deteriorated glucose tolerance status groups was significantly lower than the stable glucose tolerance status groups [-30.3% (-70.5%, 11.3%) vs. -70.3% (-91.4%, -40.4%), P<0.05]. The changes of fasting blood glucose and growth hormone before and after SSA treatment were positively correlated with the change rate of insulin resistance index evaluated by homeostasis model ( r=0.318 and 0.251, P=0.013 and 0.030). Conclusions:SSA can increase blood glucose in some patients with GH secreting adenomas. The outcome of glucose metabolism depends on the drug sensitivity. Moreover, young patients with poor drug efficacy are more likely to suffer from the deterioration of glucose metabolism after SSA treatment.

Effects of somatostatin receptor ligands on bone metabolism in acromegaly

Efficacy and Predictors of Short-Term First-Generation Somatostatin Analog Presurgical Treatment in Acromegaly: A Hospital-Based Study of 237 Cases.

Sclerostin and OPG/RANK-L system take part in bone remodeling in patients with acromegaly

Effects of Long-Acting Somatostatin Analogues on Lipid Metabolism in Patients with Newly Diagnosed Acromegaly: A Retrospective Study of 120 Case S

The Change of Bone Turnover Markers and Bone Remodelling Balance in Acromegaly

Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study

Decreased Serum Wnt Antagonist Levels in Patients with Active Acromegaly

Combined Therapy of Somatostatin Analogues with Pegvisomant for the Treatment of Acromegaly: a Meta-Analysis of Prospective Studies

The Negative Impacts of Acromegaly on Bone Microstructure Not Fully Reversible

Preoperative Somatostatin Analogs Treatment in Acromegalic Patients with Macroadenomas. A Meta-Analysis

The comprehensive impact on human body induced by resolution of growth hormone excess.

Effects of long-acting somatostatin analogues on glucose metabolism in acromegalic patients without diabetes

The Value of an Acute Octreotide Suppression Test in Predicting Short-Term Efficacy of Somatostatin Analogues in Acromegaly

Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues

Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly

Presurgical Treatment with Somatostatin Analogues in Growth Hormone-Secreting Pituitary Adenomas: A Long-Term Single-Center Experience

Comparative Efficacy of Medical Treatment for Acromegaly: A Systematic Review and Network Meta-Analysis of Integrated Randomized Trials and Observational Studies

Dynamic changes in the distribution of facial and abdominal adipose tissue correlated with surgical treatment in acromegaly

Value of octreotide suppression test in predicting the efficacy of long-acting somatostatin receptor ligands in pituitary GH adenomas

The effect of octreotide treatment on somatic and psychological symptoms of acromegaly

Effects of combination therapy: somatostatin analogues and dopamine agonists on GH and IGF1 levels in acromegaly